INTRODUCTION
The filoviruses Ebola virus and Marburg virus can cause severe haemorrhagic fevers that are frequently fatal (Mahanty & Bray, 2004) . Marburg and Ebola envelope glycoproteins consist of a GP1 protein and membranebound GP2 protein that are covalently linked by a disulfide bond (Sanchez et al., 1996) . Although the causes of filovirus virulence are not well defined, there is evidence that glycans on the viral glycoproteins play distinct roles in pathogenesis (Takada & Kawaoka, 2001) . For example, expression of Ebola glycoprotein in cells causes a reduction in host cell-surface protein expression that is associated with cell rounding and detachment (Simmons et al., 2002; Sullivan et al., 2005) . Removal of O-linked carbohydrates from the glycoprotein reduces the cell rounding and detachment. Additionally, the Ebola envelope glycoprotein interacts with the cell-surface lectins DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin) and DC-SIGNR (DC-SIGN-related molecule), which are expressed on several potential target cells including dendritic cells, alveolar macrophages and endothelial cells in the liver (Alvarez et al., 2002; Baribaud et al., 2002; Lin et al., 2003; Simmons et al., 2003) . The Ebola glycoprotein carbohydrate that interacts with DC-SIGN is likely to contain mannose residues, since DC-SIGN and DC-SIGNR have a high affinity for high-mannose sites on N-linked glycans and because the interaction is inhibited by the high-mannose carbohydrate mannan (Alvarez et al., 2002; Feinberg et al., 2001) . Further evidence that mannose residues are displayed prominently on Ebola glycoprotein is that cyanovirin-N inhibits Ebola virus infection of cells (Barrientos et al., 2003 (Barrientos et al., , 2004b . Cyanovirin-N is an antiviral lectin derived from cyanobacteria, which binds to mannose residues of N-linked glycans (Botos & Wlodawer, 2003) .
Mannose-binding lectin (MBL) is a C-type lectin found in serum with specificity for mannose, N-acetylglucosamine and fucose (Hansen & Holmskov, 1998) . MBL has several important innate immune functions including initiation of the lectin complement pathway, opsonization of microbes for uptake by phagocytic cells and direct neutralization of some viruses (Jack et al., 2001; Matsushita & Fujita, 2001; Petersen et al., 2001) . MBL binds strongly to human immunodeficiency virus type 1 (HIV-1), and high-mannose N-linked glycans on the HIV-1 glycoprotein gp120 are critical for this interaction (Ezekowitz et al., 1989; Hart et al., 2002; Haurum et al., 1993; Ohtani et al., 1999; Saifuddin et al., 2000) . HIV-1 gp120 also binds to DC-SIGN, DC-SIGNR and cyanovirin-N through high-mannose N-linked glycans (Bashirova et al., 2001; Bolmstedt et al., 2001; Esser et al., 1999; Geijtenbeek et al., 2000) . Since Ebola virus interacts with DC-SIGN, DC-SIGNR and cyanovirin-N, we hypothesized that the Ebola glycoprotein would also bind to MBL. This study assessed the ability of Ebola and Marburg virus glycoprotein-pseudotyped viruses to bind to immobilized MBL and to activate the lectin complement pathway. We also evaluated the ability of MBL to inhibit interaction between the Ebola virus glycoprotein and DC-SIGN. Virus pseudotyped with the envelope glycoprotein of vesicular stomatitis virus (VSV-G) was used as a control in these experiments, since both VSV and HIV particles pseudotyped with VSV-G are neutralized by the classical pathway of human complement (Beebe & Cooper, 1981; DePolo et al., 2000) .
METHODS
Cell lines and reagents. Human embryonic kidney 293 cells were obtained from the AIDS Research and Reference Reagent Program (ARRRP), National Institutes of Health (NIH, Rockville, MD, USA), and cultured in Dulbecco's modified Eagle's medium containing 10 % heat-inactivated fetal bovine serum, 1 % L-glutamine and 50 mg gentamicin (BioWhittaker) ml 21 . The B-THP-1 cell line (Wu et al., 2004) expressing DC-SIGN and control DC-SIGN-negative cells were kindly provided by Dr Dan Littman (New York University School of Medicine, NY, USA) and grown in RPMI 1640 (BioWhittaker) containing 10 % heat-inactivated fetal bovine serum, L-glutamine and gentamicin. Sera from two donors (one male aged 49 years, one female aged 30 years) with normal levels of MBL (3?9 and 4?8 mg ml
21
, respectively, as determined by ELISA; Statens Serum Institut, Copenhagen, Denmark) were pooled as a complement source (normal human pooled sera, NHPS). Sera from three MBL-deficient donors (0?4-0?8 mg ml
) were pooled as a source of MBL-deficient complement (MBL-deficient pooled sera, MDPS). The three donors were all healthy females, aged 22-38 years. All donors were recruited from healthy laboratory personnel. To inactivate complement, pooled sera were heat inactivated at 56 uC for 1 h.
As described previously (Hart et al., 2003) , supernatants from a human liver fibroblast cell line infected with recombinant vaccinia virus expressing human recombinant MBL (rMBL) were collected and rMBL was purified on a mannan-Sepharose 4B column. MBL was also purified from freshly frozen plasma as previously described (Suankratay et al., 1998) . Briefly, MBL was affinity isolated using mannan-coupled Sepharose, passed over protein A-Sepharose to remove residual immunoglobulins and concentrated. The concentration of MBL was determined by ELISA.
Preparation of pseudotyped viruses. HIV particles lacking gp120/gp41 and pseudotyped with Ebola and Marburg envelope proteins were used in all experiments since filoviruses present a significant biohazard (Chan et al., 2000) . Pseudotyped viruses were prepared by co-transfecting 293 cells using Lipofectamine (Gibco-BRL) with env-negative HIV plasmid pNL 4-3 (E Binding of pseudotyped viruses to MBL. Flat-bottomed, 96-well polystyrene tissue culture plates (Costar) were coated overnight with 100 ml of either BSA or rMBL (10 mg ml
) diluted in veronalbuffered saline (VBS-Ca: 5 mM veronal pH 7?5, 0?15 M NaCl and 10 mM CaCl 2 ). Wells were blocked with 1 % BSA, washed with VBS-Ca and incubated for 4 h with 100 ml pseudotyped virus (8 ng p24 ml 21 ) diluted in VBS-Ca. Wells were washed with VBS-Ca, bound viruses were lysed with 0?25 % Triton X-100 and p24 was detected by ELISA. The percentage of p24 bound for each virus was calculated as: [(p24 bound in MBL-coated wells2background binding to BSA-coated wells)/(input p242background binding)] 6100.
Binding of pseudotyped viruses to DC-SIGN. Virus pseudotyped with the Ebola envelope glycoprotein was pre-incubated with rMBL (0-10 mg p24 ml 21 ) for 1 h at 37 uC before incubation with 1610 6 DC-SIGN + or DC-SIGN 2 THP-1 cells for 3 h at 37 uC. Cells were washed, lysed with detergent (0?2 % Tween 20) and cellbound virus was measured by p24 ELISA.
Measurement of lectin complement pathway activity. Lectin pathway-dependent C4 deposition was assayed as previously described (Valdimarsson et al., 1998) . Microtitre plate wells (Maxisorp Nunc) were coated overnight with 10 mg mannan ml 21 and wells were then blocked with 1 % BSA. Sera diluted in buffer containing 20 mM Tris/HCl pH 7?4, 10 mM CaCl 2 , 1 M NaCl, 0?05 % Triton X-100 and 1 % BSA (100 ml per well) were incubated in wells overnight at 4 uC. Purified C4 (12 mg per well; Calbiochem) was added to each well and incubated for 1?5 h at 37 uC. Wells were washed, 8 ng biotinylated goat anti-human C4 antibody (Calbiochem) was added per well and wells were incubated at room temperature for 1 h. Wells were washed and streptavidin-HRP (Biosource) was added to the wells for 45 min at 37 uC. After further washing, substrate was added and the absorbance at 405 nm was determined. Pseudotyped viruses were incubated with dilutions of NHPS, MDPS or heat-inactivated sera at 37 uC for 50 min. Treated virus (100 ml) was transferred to 48-well flat-bottomed culture plates containing 0?7610 5 293 cells per well. Plates were centrifuged at 1000 g for 2 h at 25 uC to facilitate infection (Ying et al., 2004) and then incubated for 4 h at 37 uC. The virus-complement mixture was replaced with fresh medium and cells were harvested after 40 h of culture. Luciferase activity in cells was measured and neutralization calculated by the formula: neutralization (%)=1002(complementtreated luciferase units/heat-inactivated complement luciferase units)6100.
RESULTS

Binding of pseudotyped viruses to MBL
Previous studies have shown that MBL binds HIV via highmannose carbohydrate residues on gp120/gp41 (Hart et al., 2002) , while HIV virions lacking gp120/gp41 bind at relatively low levels to MBL (Saifuddin et al., 2000) . To determine whether filovirus glycoproteins interact with MBL, viruses pseudotyped with Ebola, Marburg, HIV or VSV envelope glycoproteins were incubated in rMBL-coated microtitre wells. HIV particles lacking a viral envelope glycoprotein (gp120 2 ) bound at relatively low levels to MBL (0?2 % of input; Fig. 1 ), while HIV particles containing HIV envelope glycoprotein (gp120 + ) bound at significantly higher levels to MBL (3?1 % of input, P<0?05, t-test). As an additional control, we assessed binding to MBL of virus pseudotyped with VSV-G since these virus particles activate the classical, but not the lectin, complement pathway (DePolo et al., 2000) . HIV particles pseudotyped with VSV-G bound to MBL at significantly lower levels than HIV (0?6 % of input, P<0?05), although binding was consistently higher than binding of particles with no viral glycoproteins. Particles pseudotyped with Ebola (Zaire) and Marburg (Musoke) envelope proteins bound at significantly higher levels (4?1 and 3?0 %, respectively) than gp120
2 -or VSV-G-pseudotyped particles (P<0?05 vs gp120 2 ). In contrast, particles pseudotyped with Marburg (Ravn) bound at a level (1?3 %) intermediate between gp120
2 -and Ebola-pseudotyped particles. These data showed that incorporation of Ebola and Marburg virus envelope glycoproteins into HIV particles significantly increased the ability of virus particles to interact with MBL.
MBL blocks Ebola virus glycoprotein interaction with DC-SIGN
Previous studies have shown that Ebola virus envelope glycoprotein binds to the dendritic cell lectin DC-SIGN (Alvarez et al., 2002; Baribaud et al., 2002; Lin et al., 2003; Simmons et al., 2003) . We evaluated the ability of MBL to block binding of Ebola-pseudotyped particles to cells expressing DC-SIGN. Ebola-pseudotyped virus bound at significantly higher levels to DC-SIGN-expressing THP-1 cells than to control DC-SIGN 2 THP-1 cells (Fig. 2 
Complement-dependent neutralization of pseudotyped viruses
Since the above experiments indicated that MBL binds to filovirus glycoproteins on the surface of virus particles, we wanted to determine whether MBL could directly neutralize virus pseudotyped with the Ebola virus glycoprotein. No neutralization of infection of 293 cells was observed when virus was pre-incubated with 10 or 30 mg MBL ml 21 for 1 h at 37 u C (not shown). We next determined whether the lectin complement pathway was activated, as assessed by neutralization. Two pools of sera were used as sources of complement in neutralization assays: NHPS, a pool of equal volumes of sera from two individuals with normal levels of serum MBL, and MDPS, a pool of sera from three individuals with low levels of serum MBL. Previous studies have shown that when MBL in serum binds to immobilized mannan it activates MBL-associated serine proteases leading to activation of C4 (Valdimarsson et al., 1998) . Therefore, in order to compare the lectin pathway activity of the two serum pools, the complement sources were diluted and added to mannan-coated microtitre wells. Addition of NHPS to mannan-coated wells resulted in detectable C4 deposition with dilutions from 1 : 3 to 1 : 30 (Fig. 3) , while, in contrast, MDPS induced lower C4 deposition at these dilutions. For example, a 1 : 3 dilution of MDPS and a 1 : 30 dilution of NHPS resulted in similar C4 activation. Thus, lectin complement pathway activation in MDPS was lower by approximately five-to tenfold compared with NHPS.
Neutralization of VSV-G-pseudotyped particles by sera was next evaluated, since previous studies have shown that these virus particles interact with natural IgM antibodies in sera, resulting in neutralization by the classical complement pathway (Beebe & Cooper, 1981; DePolo et al., 2000) . NHPS at low dilutions (1 : 2 and 1 : 4) significantly neutralized VSV-G-pseudotyped particles compared with heat-inactivated NHPS (Fig. 4a) . When expressed as the percentage of neutralization, VSV-G-pseudotyped virus was neutralized by 98, 97 and 59 % by 1 : 2, 1 : 4 and 1 : 8 dilutions of NHPS, respectively (Fig. 4b) . MDPS neutralized VSV-G-pseudotyped virus at levels similar to NHPS (Fig. 4b ).
Ebola-pseudotyped virus was also neutralized by NHPS, although neutralization was less than with VSV-G-pseudotyped virus with 85, 60 and 10 % neutralization with 1 : 2, 1 : 4 and 1 : 8 dilutions of NHPS, respectively (Fig. 4c) . MDPS was significantly less effective in neutralizing Ebolapseudotyped virus at a 1 : 2 dilution (50 % neutralization, Fig. 4c ), but at 1 : 4 and 1 : 8 dilutions NHPS and MDPS neutralized Ebola-pseudotyped virus at similar levels. Thus, complement efficiently neutralized Ebolapseudotyped virus, and MBL-deficient complement was less Microtitre wells were coated with mannan. Dilutions of normal human pooled sera (NHPS) or MBL-deficient pooled sera (MDPS) were incubated in mannan-coated wells overnight at 4 6C to allow binding of MBL. After washing, purified C4 was added to each well and incubated for 1?5 h at 37 6C. Wells were subsequently incubated with biotinylated anti-C4, streptavidin-HRP and substrate. One experiment representative of two independent experiments is shown. effective at neutralization, indicating that neutralization was partially mediated through the lectin complement pathway.
Viruses pseudotyped with either Ebola, Marburg (Musoke) or Marburg (Ravn) glycoproteins were compared next using the highest concentration of complement (1 : 2 dilution of sera). The Ebola-and Marburg (Musoke)-pseudotyped viruses were 87 and 85 % neutralized, respectively, while Marburg (Ravn)-pseudotyped virus was 65 % neutralized by treatment with NHPS (Fig. 4d) . In contrast, MDPS neutralized each pseudotyped virus at significantly lower levels than NHPS (Fig. 4d) .
To confirm that MBL plays a role in neutralizing the Ebola glycoprotein-pseudotyped virus, we assessed the effect on neutralization of reconstituting the lectin complement pathway in MDPS by adding MBL. Addition of 10 mg purified MBL ml 21 to heat-inactivated MDPS did not increase neutralization of the Ebola glycoproteinpseudotyped virus when compared with heat-inactivated MDPS alone (Fig. 5) . In contrast, addition of MBL to MDPS significantly neutralized the pseudotyped virus when compared with MDPS alone (Fig. 5 ).
DISCUSSION
The current study is the first description of MBL binding to Ebola and Marburg glycoproteins. MBL binding effectively blocked Ebola glycoprotein interactions with DC-SIGN. Furthermore, when other complement components were present, the lectin pathway initiated by MBL neutralized virus pseudotyped with the filovirus glycoproteins.
Filovirus infections are associated with both the inability to mount effective adaptive immune responses and downregulation of innate immune responses (Bray, 2001; Geisbert et al., 2003; Mahanty & Bray, 2004; Reed et al., 2004; Sanchez et al., 2004) . While vaccination has been investigated as a way of boosting adaptive immune responses to filoviruses and increase survival during infection, few studies have evaluated innate immunity. Innate immune responses are an important early response by the host, since they can inhibit viral growth while simultaneously initiating and modulating adaptive immune responses Biron, 1998; Biron et al., 1999; Hackett, 2003; . In the mouse model of Ebola, the innate immune response, and specifically type I interferon production, was shown to be important for protection (Bray, 2001; Mahanty et al., 2003) , while the viral protein VP35 functions as an interferon antagonist (Basler et al., 2000 (Basler et al., , 2003 . More recently, Warfield et al. (2004) demonstrated a role for NK cells in protection when mice were vaccinated with Ebola virus-like particles. While these observations describe antiviral effects of the innate immune response, only a few studies have evaluated the role of the complement system. One study compared complement levels with Ebola virus-induced disease outcome (Zabavichene & Chepurnov, 2004) and an association between complement activation and lethal outcome in guinea pigs was observed. Specifically, early activation followed by a steady decline in complement activity was associated with a lethal outcome. Takada and co-workers showed that complement component C1q mediated antibodydependent enhancement of Ebola infection in vitro. In contrast, a potential beneficial role for complement in adaptive responses was demonstrated by Wilson et al. (2000) , since complement boosted neutralization of Ebola by monoclonal antibodies. Similarly, in vitro neutralization of Marburg virus by specific monoclonal antibodies was dependent on complement (Hevey et al., 2003) . Interactions between filoviruses and the lectin or alternative complement pathways have not been investigated.
MBL recognizes a variety of clinically relevant pathogens by binding to repeating sugar structures found on exposed proteins (Ezekowitz, 2003) . For example, MBL binds to influenza virus, herpes simplex virus type 2 and HIV through N-linked high-mannose carbohydrate structures on their respective glycoproteins (Anders et al., 1994; Gadjeva et al., 2004; Hartshorn et al., 1993; Reading et al., 1995; Saifuddin et al., 2000) . The GP1 and GP2 glycoproteins of filoviruses are heavily glycosylated and predicted to have both N-linked and O-linked carbohydrate structures (Feldmann et al., 1994; Geyer et al., 1992) , although Olinked carbohydrates are rarely terminated with mannose residues. DC-SIGN and cyanovirin-N, which bind to Nlinked high-mannose oligosaccharides, have been shown to bind to Ebola and Marburg glycoproteins (Alvarez et al., 2002; Barrientos et al., 2003 Barrientos et al., , 2004a Marzi et al., 2004; Simmons et al., 2003) . A role for macrophage cell-surface Ctype lectin in binding the virus has also been demonstrated (Takada et al., 2004 ). In the current study, the existence of high-mannose N-linked carbohydrate structures on a filovirus envelope protein was supported by the demonstration that MBL binds to both Ebola and Marburg virus glycoproteins. Overall, binding of the Ebola and Marburg (Musoke) glycoprotein-pseudotyped viruses to MBL was similar to binding of HIV. There was less binding by Marburg (Ravn)-pseudotyped virus to MBL. These differences in binding may be due to different glycosylation patterns in the envelope glycoproteins. An analysis of GenBank sequences shows that the Ravn and Musoke strains are only 70 % homologous in amino acid sequence. Furthermore, while Ebola and Marburg viruses share a number of predicted N-linked glycosylation sites, there are also sites that differ between the two. Similarly, Marburg strains appear to share some N-linked sites but are divergent at other sites. As expected, the VSV-pseudotyped virus did not bind efficiently to MBL, presumably because VSV-G lacks high-mannose carbohydrate structures. VSV-G contains only two to six potential glycosylation sites (Coll, 1995) .
In this study, neutralization of filoviruses was dependent on complement activity since heat inactivation reduced neutralization. However, MBL has been shown to alter virus infectivity directly by mechanisms that are independent of complement activation. Thus, MBL neutralizes influenza A virus by blocking glycoprotein interactions with receptors and viral aggregation (Hartshorn et al., 1997; Saifuddin et al., 2000) . MBL could neutralize filoviruses by similar mechanisms. While several potential receptors have been proposed for Ebola, DC-SIGN and C-type lectins specific for galactose and N-acetylgalactosamine have been implicated as an Ebola-binding protein (Alvarez et al., 2002; Takada et al., 2004) . In the absence of complement, MBL treatment of virus blocked the Ebola glycoprotein-mediated attachment to cells expressing DC-SIGN. During infection, MBL binding to circulating virus could effectively reduce viral infection of lectin-expressing cells, including dendritic cells that modulate later adaptive responses.
There is disagreement on the role of MBL in disease progression due to viral agents. For example, there are conflicting reports on the association between MBL variants and HIV infections (Ji et al., 2005) . A large percentage of the population are MBL deficient and low MBL levels could have a significant impact on viral infection. Despite the ability of MBL to bind and inhibit filovirus glycoproteinpseudotyped virus infection in vitro, natural disease in humans is characterized by explosive virus replication with high mortality. No study has evaluated MBL expression in the populations that have been afflicted with filovirus disease. The current study suggests that MBL levels in patients should be studied. Alternatively, filoviruses could avoid complement activity by a variety of ways (Spear et al., 2001) . Binding of MBL to virus and subsequent deposition of complement components on the viral membrane could lead to enhanced virus infection of cells that express complement receptors. Furthermore, as observed with other enveloped viruses, filoviruses may incorporate host complement control proteins that would limit the ability of complement to eliminate the cell-free virus.
In summary, we have demonstrated the ability of MBL, a recognition and effector molecule of the innate immune system, to bind to filovirus glycoproteins, resulting in antiviral activity. These findings suggest that human MBL may play important roles in innate immunity during filovirus infections such as direct inhibition of infection and inhibition of viral spread, as well as mediating opsonization and complement activation. Further studies are needed to evaluate the role of MBL and complement during filovirus infections.
